Table 2 Uncomplicated malaria case management indicators among patients exiting facilities in the Busoga sub-region
Variable | All | Level | Ownership | Age category | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
IV | III | II | GOU | PNFP | PFP | 0–4 | 5 -14 | 14–44 |  > 45 | ||
Total number of patients enrolled, N | 3936 | 363 | 1398 | 2175 | 3414 | 323 | 199 | 1235 | 776 | 1643 | 282 |
Documentation of information | |||||||||||
 Age, n (%) | 3612 (91.8) | 324 (89.3) | 1298 (92.9) | 1990 (91.5) | 3131 (91.7) | 292 (90.4) | 189 (94.9) | 1156 (93.6) | 715 (92.1) | 1476 (89.8) | 265 (94.0) |
 Prior use of anti-malarials, n (%) | 214 (5.4) | 5 (1.4) | 69 (4.9) | 140 (6.4) | 136 (3.9) | 42 (13.0) | 36 (18.1) | 45 (3.6) | 39 (5.0) | 109 (6.6) | 21 (7.4) |
 Temperature, n (%) | 649 (24.3) | 34 (11.6) | 385 (29.9) | 230 (21.0) | 440 (20.2) | 127 (43.3) | 82 (41.2) | 221 (25.9) | 114 (22.0) | 274 (24.1) | 40 (24.2) |
 Weight, n (%) | 2842 (79.7) | 245 (67.5) | 1147 (83.7) | 1450 (79.0) | 2490 (81.1) | 249 (83.5) | 103 (51.8) | 891 (80.6) | 586 (81.9) | 1150 (77.8) | 215 (79.9) |
Malaria testing | |||||||||||
 Suspects  tested, n (%) | 3552 (90.2) | 317 (87.3) | 1330 (95.1) | 1905 (87.6) | 3128 (91.6) | 290 (89.8) | 134 (67.3) | 1121 (90.8) | 690 (88.9) | 1488 (90.6) | 253 (89.7) |
 Test positivity rate, n (%) | 2106 (59.3) | 191 (60.3) | 715 (53.8) | 1200 (63.0) | 1894 (60.5) | 139 (47.9) | 73 (54.5) | 715 (63.8) | 522 (75.6) | 749 (50.3) | 120 (47.4) |
Malaria test: RDT, n (%) | 3040 (85.6) | 124 (39.1) | 1086 (81.6) | 1830 (96.1) | 2721 (87.0) | 246 (84.8) | 73 (54.5) | 959 (85.6) | 600 (87.0) | 1265 (85.0) | 216 (85.4) |
Anti-malarial treatment prescribed | |||||||||||
Among tested positive, n (%) | 2094 (99.4) | 190 (99.5) | 704 (98.5) | 1200 (100.0) | 1886 (99.6) | 136 (97.8) | 72 (98.6) | 713 (99.7) | 520 (99.6) | 744 (99.3) | 117 (97.5) |
Among tested negative, n (%) | 25 (1.7) | 1 (0.8) | 9 (1.5) | 15 (2.1) | 22 (1.8) | 3 (2.0) | 0 | 19 (4.7) | 2 (1.2) | 3 (0.4) | 1 (0.8) |
Among not tested, n (%) | 216 (56.3) | 10 (21.7) | 16 (23.5) | 190 (70.4) | 134 (46.9) | 22 (66.7) | 60 (92.3) | 80 (70.2) | 68 (79.1) | 56 (36.1) | 12 (41.4) |
Anti-malarial types prescribed | |||||||||||
 AL | 1991 (95.1) | 175 (92.1) | 671 (95.3) | 1145 (95.4) | 1821 (96.6) | 130 (95.6) | 40 (55.6) | 667 (93.6) | 498 (95.7) | 710 (95.4) | 116 (99.1) |
 AL + SP | 1 (0.05) | 1 (0.5) | 0 | 0 | 1 (0.1) | 0 | 0 | 1 (0.1) | 0 | 0 | 0 |
 AL + TQ | 1 (0.05) | 0 | 1 (0.1) | 0 | 1 (0.1) | 0 | 0 | 1 (0.1) | 0 | 0 | 0 |
 AL + MQ | 5 (0.2) | 0 | 0 | 5 (0.4) | 5 (0.3) | 0 | 0 | 0 | 5 (0.9) | 0 | 0 |
 IV AS + AL | 30 (1.4) | 6 (3.0) | 14 (2.0) | 10 (0.8) | 29 (1.5) | 1 (0.7) | 0 | 16 (2.2) | 12 (2.3) | 1 (0.1) | 1 (0.9) |
 DP | 33 (1.6) | 4 (2.1) | 9 (1.3) | 20 (1.7) | 17 (0.9) | 1 (0.7) | 15 (20.8) | 9 (1.3) | 3 (0.6) | 21 (2.8) | 0 |
 IM  rtemether | 2 (0.1) | 0 | 2 (0.3) | 0 | 0 | 1 (0.7) | 1 (1.4) | 1 (0.1) | 1 (0.2) | 0 | 0 |
 Piperaquine | 5 (0.2) | 0 | 0 | 5 (0.4) | 5 (0.3) | 0 | 0 | 0 | 0 | 5 (0.7) | 0 |
 Quinine | 1 (0.05) | 0 | 1 (0.1) | 0 | 0 | 0 | 1 (1.4) | 1 (0.1) | 0 | 0 | 0 |
 Amodiaqu ne | 1 (0.05) | 0 | 1 (0.1) | 0 | 0 | 1 (1.5) | 0 | 0 | 0 | 1 (0.1) | 0 |
 Oral rtesunate | 1 (0.05) | 1 (0.5) | 0 | 0 | 1 (0.1) | 0 | 0 | 1 (0.1) | 0 | 0 | 0 |
 IV AS | 23 (1.1) | 3 (1.6) | 5 (0.7) | 15 (1.2) | 6 (0.5) | 2 (3.1) | 15 (20.8) | 16 (2.2) | 1 (0.2) | 6 (0.8) | 0 |
Appropriate MCM; AL prescribed, n (%) | 3419 (86.9) | 301 (82.9) | 1278 (91.4) | 1820 (84.6) | 3040 (89.1) | 278 (86.1) | 101 (50.7) | 1056 (85.5) | 669 (86.2) | 1446 (88.0) | 248 (87.9) |
Appropriate MCM; ACT prescribed, n (%) | 3464 (88.0) | 306 (84.3) | 1298 (92.9) | 1860 (85.5) | 3065 (89.8) | 282 (87.3) | 117 (58.8) | 1067 (86.4) | 674 (86.8) | 1472 (89.6) | 251 (89.0) |
Appropriate MCM; AL given, n (%) | 3034 (77.1) | 230 (63.4) | 1134 (81.1) | 1670 (76.8) | 2671 (78.2) | 268 (82.9) | 95 (47.7) | 931 (75.4) | 566 (72.9) | 1320 (80.3) | 217(77.0) |
Patient satisfaction score1, median (IQR) | 8 (6, 9) | 7 (6, 8) | 8 (6, 9) | 8 (7, 9) | 8 (6, 9) | 8 (7, 9) | 9 (8, 10) | 8 (7, 9) | 8 (6, 9) | 8 (6, 9) | 8 (6, 9) |